4DMT to Participate in Upcoming Investor Conferences
4D Molecular Therapeutics (Nasdaq: FDMT), a late-stage biotechnology company, has announced its participation in the upcoming RBC Capital Markets 2025 Ophthalmology Conference. The virtual event is scheduled for April 3-4, 2025, where the company's management will engage in a fireside chat and be available for one-on-one meetings.
The company, focused on developing durable and disease-targeted therapeutics, aims to transform treatment paradigms. Interested parties can access an archived recording of the webcast for up to one year through the 'Investors' section on 4DMT's website.
4D Molecular Therapeutics (Nasdaq: FDMT), un'azienda biotecnologica in fase avanzata, ha annunciato la sua partecipazione alla prossima Conferenza sull'Oftalmologia 2025 di RBC Capital Markets. L'evento virtuale è programmato per il 3-4 aprile 2025, durante il quale la direzione dell'azienda parteciperà a una conversazione informale e sarà disponibile per incontri individuali.
L'azienda, focalizzata sullo sviluppo di terapie durevoli e mirate alle malattie, mira a trasformare i paradigmi di trattamento. Le parti interessate possono accedere a una registrazione archiviata del webcast per un massimo di un anno attraverso la sezione 'Investitori' sul sito web di 4DMT.
4D Molecular Therapeutics (Nasdaq: FDMT), una empresa biotecnológica en etapa avanzada, ha anunciado su participación en la próxima Conferencia de Oftalmología 2025 de RBC Capital Markets. El evento virtual está programado para los días 3 y 4 de abril de 2025, donde la dirección de la empresa participará en una charla informal y estará disponible para reuniones uno a uno.
La empresa, centrada en el desarrollo de terapias duraderas y dirigidas a enfermedades, tiene como objetivo transformar los paradigmas de tratamiento. Las partes interesadas pueden acceder a una grabación archivada de la transmisión web durante un año a través de la sección 'Inversores' en el sitio web de 4DMT.
4D Molecular Therapeutics (Nasdaq: FDMT), 후기 단계 생명공학 회사가 다가오는 RBC Capital Markets 2025 안과학 회의에 참여한다고 발표했습니다. 이 가상 이벤트는 2025년 4월 3-4일로 예정되어 있으며, 회사 경영진이 대담에 참여하고 일대일 미팅을 위해 참석할 예정입니다.
회사는 지속 가능하고 질병 표적 치료제를 개발하는 데 중점을 두고 있으며, 치료 패러다임을 변화시키는 것을 목표로 하고 있습니다. 관심 있는 분들은 4DMT 웹사이트의 '투자자' 섹션을 통해 최대 1년 동안 웹캐스트의 아카이브 녹음을 이용할 수 있습니다.
4D Molecular Therapeutics (Nasdaq: FDMT), une entreprise de biotechnologie en phase avancée, a annoncé sa participation à la prochaine Conférence sur l'Ophthalmologie 2025 de RBC Capital Markets. L'événement virtuel est prévu pour les 3 et 4 avril 2025, au cours duquel la direction de l'entreprise participera à une discussion informelle et sera disponible pour des réunions individuelles.
L'entreprise, axée sur le développement de thérapies durables et ciblées sur les maladies, vise à transformer les paradigmes de traitement. Les parties intéressées peuvent accéder à un enregistrement archivé du webcast pendant un an via la section 'Investisseurs' sur le site web de 4DMT.
4D Molecular Therapeutics (Nasdaq: FDMT), ein Unternehmen der Biotechnologie in der späten Entwicklungsphase, hat seine Teilnahme an der bevorstehenden RBC Capital Markets 2025 Augenheilkunde-Konferenz angekündigt. Die virtuelle Veranstaltung ist für den 3. und 4. April 2025 geplant, bei der das Management des Unternehmens an einem informellen Gespräch teilnehmen und für Einzelgespräche zur Verfügung stehen wird.
Das Unternehmen, das sich auf die Entwicklung von dauerhaften und krankheitszielgerichteten Therapeutika konzentriert, zielt darauf ab, die Behandlungsparadigmen zu verändern. Interessierte Parteien können über den Bereich 'Investoren' auf der Website von 4DMT auf eine archivierte Aufzeichnung des Webcasts zugreifen, die bis zu einem Jahr verfügbar ist.
- None.
- None.
EMERYVILLE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in a fireside chat at the upcoming RBC Capital Markets 2025 Ophthalmology Conference being held virtually on April 3-4, 2025. Members of the management team will also be available for one-on-one meetings.
RBC Capital Markets 2025 Ophthalmology Conference
| Presentation Date: | Thursday, April 3, 2025 |
| Presentation Time: | 9:15 a.m. ET |
| Webcast Link: | Webcast |
An archived copy of the webcast will be available for up to one year on the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Our lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Our lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. Our second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts:
Media:
Jenn Gordon
dna Communications
Media@4DMT.com
Investors:
Julian Pei
Head of Investor Relations and Corporate Finance
Investor.Relations@4DMT.com
FAQ
When is 4DMT (FDMT) participating in the RBC Capital Markets Ophthalmology Conference 2025?
What type of presentation will FDMT give at the RBC Capital Markets Conference?
How long will the FDMT conference webcast be available for viewing?
Where can investors access FDMT's RBC Conference presentation recording?
